Harpoon Therapeutics

Harpoon Therapeutics is an immuno-oncology company focused on developing novel biologics for cancer treatment using its proprietary TriTAC technology platform. The company's approach aims to harness the power of a patient's own immune system to target and kill cancer cells. Harpoon Therapeutics has recently been acquired by Merck, further expanding the company's capabilities and pipeline in the field of oncology.